Optimal Management of High-Risk CLL with Acalabrutinib

Part 1 - Welcome address by Dr. M B Agarwal, Mumbai

Part 2 - Risk stratification in CLL - Dr. P G Subramanian, Mumbai

Part 3 - Management of high-risk CLL with acalabrutinib - Dr. Harshit Khurana, Pune

Part 4 - Case-based panel discussion - Dr. M B Agarwal, Mumbai

Part 5 - Vote of Thanks - Ms. Rupa Sharma, Astra Zeneca